Theravance Biopharma (NASDAQ:TBPH) Shares Up 4.6% - Should You Buy?

Key Points

• Theravance Biopharma's shares rose 4.6% to $14.33, with trading volume increasing 8% compared to the average, showing strong market interest.
• Analysts have upgraded the stock multiple times, with Zacks Research and Wall Street Zen both raising their ratings to "strong-buy" and setting a consensus price target of $23.00.
• Insider activity indicates confidence in the company, as 6.90% of the stock is owned by insiders, while institutional investors hold 99.10% of the shares.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s share price shot up 4.6% during trading on Friday . The stock traded as high as $14.25 and last traded at $14.33. 313,270 shares were traded during mid-day trading, an increase of 8% from the average session volume of 289,849 shares. The stock had previously closed at $13.70.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TBPH shares. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. BTIG Research lifted their target price on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research note on Tuesday, June 17th. B. Riley assumed coverage on Theravance Biopharma in a report on Friday. They set a "buy" rating and a $28.00 price objective for the company. Finally, Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $23.00.

Theravance Biopharma Price Performance

The stock has a fifty day moving average price of $12.33 and a 200-day moving average price of $10.56. The company has a market cap of $703.53 million, a PE ratio of 58.13 and a beta of 0.05.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Theravance Biopharma by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock worth $18,579,000 after acquiring an additional 69,919 shares in the last quarter. Park West Asset Management LLC boosted its holdings in Theravance Biopharma by 0.6% in the 1st quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock valued at $16,112,000 after purchasing an additional 11,256 shares during the period. Geode Capital Management LLC raised its position in Theravance Biopharma by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company's stock worth $9,863,000 after purchasing an additional 3,416 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Theravance Biopharma by 9.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock worth $7,847,000 after acquiring an additional 69,178 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Theravance Biopharma by 16.5% in the second quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company's stock worth $5,952,000 after buying an additional 76,417 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.